Verweij J - Search Results

1

Clinical pharmacokinetics of docetaxel : recent developments.

Baker SD, Sparreboom A, Verweij J. Baker SD, et al. Among authors: verweij j. Clin Pharmacokinet. 2006;45(3):235-52. doi: 10.2165/00003088-200645030-00002. Clin Pharmacokinet. 2006. PMID: 16509758 Review.

2

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. ten Tije AJ, et al. Among authors: verweij j. Clin Pharmacokinet. 2003;42(7):665-85. doi: 10.2165/00003088-200342070-00005. Clin Pharmacokinet. 2003. PMID: 12844327 Review.

3

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Clin Pharmacol Ther. 2003 Oct;74(4):364-71. doi: 10.1016/S0009-9236(03)00222-4. Clin Pharmacol Ther. 2003. PMID: 14534523

4

Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.

Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A. Baker SD, et al. Among authors: verweij j. Anal Biochem. 2004 Jan 15;324(2):276-84. doi: 10.1016/j.ab.2003.09.038. Anal Biochem. 2004. PMID: 14690692

5

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Baker SD, et al. Among authors: verweij j. Clin Cancer Res. 2004 Mar 15;10(6):1976-83. doi: 10.1158/1078-0432.ccr-0842-03. Clin Cancer Res. 2004. PMID: 15041715 Clinical Trial.

6

Relationship of systemic exposure to unbound docetaxel and neutropenia.

Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A. Baker SD, et al. Among authors: verweij j. Clin Pharmacol Ther. 2005 Jan;77(1):43-53. doi: 10.1016/j.clpt.2004.09.005. Clin Pharmacol Ther. 2005. PMID: 15637530

7

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD. Rudek MA, et al. Among authors: verweij j. Eur J Cancer. 2004 May;40(8):1170-8. doi: 10.1016/j.ejca.2003.12.026. Eur J Cancer. 2004. PMID: 15110880

8

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Sparreboom A, et al. Among authors: verweij j. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25;773(2):183-90. doi: 10.1016/s1570-0232(02)00167-8. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 12031845

9

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A. Baker SD, et al. Among authors: verweij j. J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8. doi: 10.1093/jnci/94.24.1883. J Natl Cancer Inst. 2002. PMID: 12488482

10

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.

Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A. Engels FK, et al. Among authors: verweij j. Clin Pharmacol Ther. 2004 May;75(5):448-54. doi: 10.1016/j.clpt.2004.01.001. Clin Pharmacol Ther. 2004. PMID: 15116057 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

927 results

Search Page

Filters